The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The test has a complicated name: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. But the goal of the test, created by Fujirebio Diagnostics, is simple: Early detection of beta-amyloid plaques linked to the neurocognitive disease in adults 55 and older who are exhibiting signs and symptoms of the disorder.

The first Alzheimer's blood test cleared by the Food And Drug Administration is poised to change the way doctors diagnose and treat the disease.